Getagraph.com logo
S&P 500
(1.02%) 5 099.96 points
Dow Jones
(0.40%) 38 240 points
Nasdaq
(2.03%) 15 928 points
Oil
(0.11%) $83.66
Gas
(-3.32%) $1.920
Gold
(0.30%) $2 349.60
Silver
(-0.43%) $27.52
Platinum
(0.42%) $924.40
USD/EUR
(0.32%) $0.935
USD/NOK
(0.67%) $11.02
USD/GBP
(0.13%) $0.800
USD/RUB
(-0.07%) $92.11

Realaus laiko atnaujinimai Inhibrx, Inc. [INBX]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
BUY
50.00%
return 0.12%
SELL
0.00%
return 1.78%
Atnaujinta26 bal. 2024 @ 23:00
25% discount on Stockinvest.us - Use code: Podcast

-0.09% $ 34.06

PARDAVIMAS 105172 min ago

@ $37.88

Išleistas: 14 vas. 2024 @ 16:30

Grąža: -10.08%

Ankstesnis signalas: vas. 13 - 16:30

Ankstesnis signalas: Pirkimas

Grąža: 2.07 %

Live Chart Being Loaded With Signals

Commentary (26 bal. 2024 @ 23:00):

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency...

Stats
Šios dienos apimtis 189 853
Vidutinė apimtis 477 452
Rinkos kapitalizacija 1.61B
EPS $0 ( 2024-03-04 )
Kita pelno data ( $-1.040 ) 2024-05-13
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -6.65
ATR14 $0.0100 (0.03%)
Insider Trading
Date Person Action Amount type
2024-03-26 Deck Kelly Sell 625 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 396 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 1 459 Stock Option (right to buy)
2024-03-26 Deck Kelly Sell 416 Stock Option (right to buy)
2024-03-20 Deck Kelly Sell 16 777 Stock Option (right to buy)
INSIDER POWER
56.17
Last 100 transactions
Buy: 3 248 725 | Sell: 1 114 859

Tūris Koreliacija

Ilgas: -0.04 (neutral)
Trumpas: 0.24 (neutral)
Signal:(51.137) Neutral

Inhibrx, Inc. Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
BIOC0.929
NCBS0.92
FSFG0.918
SNPX0.911
SPFI0.906
BGFV0.905
EQBK0.905
SGMA0.904
PDBC0.903
ADTX0.903
10 Labiausiai neigiamai susiję koreliacijos
GDNR-0.918
BTWN-0.917
EZGO-0.906
LUNA-0.904
BRAC-0.903
MLCO-0.902
MLVF-0.902
AVAC-0.902
CBAY-0.9
IIN-0.899

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Inhibrx, Inc. Koreliacija - Valiuta/Žaliavos

The country flag -0.27
( neutral )
The country flag -0.44
( neutral )
The country flag 0.00
( neutral )
The country flag -0.36
( neutral )
The country flag -0.07
( neutral )
The country flag -0.05
( neutral )

Inhibrx, Inc. Finansinės ataskaitos

Annual 2023
Pajamos: $1.80M
Bruto pelnas: $609 000 (33.83 %)
EPS: $-5.12
FY 2023
Pajamos: $1.80M
Bruto pelnas: $609 000 (33.83 %)
EPS: $-5.12
FY 2022
Pajamos: $2.18M
Bruto pelnas: $-668 000 (-30.67 %)
EPS: $-3.62
FY 2021
Pajamos: $7.13M
Bruto pelnas: $0.00 (0.00 %)
EPS: $-2.15

Financial Reports:

No articles found.

Inhibrx, Inc.

Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.